CCIA
ADPT icon

Campbell & Co Investment Adviser’s Adaptive Biotechnologies ADPT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,609
Closed -$392K – 1060
2025
Q2 		$392K Sell
33,609
-110,331
-77% -$1M 0.02% 872
2025
Q1 		$1.07M Buy
143,940
+29,888
+26% +$230K 0.08% 405
2024
Q4 		$684K Buy
+114,052
New +$629K 0.05% 540

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's ADPT Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of Adaptive Biotechnologies (ADPT) in Q3 2025, closing a stake of 33,609 shares — an estimated $392K sold.

Campbell & Co Investment Adviser first reported a position in ADPT in Q4 2024 and held it in 3 quarters. The position peaked at $1.07M in Q1 2025. 271 funds tracked by Wall St. Rank hold ADPT as of Q3 2025.

  • Campbell & Co Investment Adviser reported no remaining Adaptive Biotechnologies position as of Q3 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 33,609 Adaptive Biotechnologies shares in Q3 2025, an estimated $392K.
  • Campbell & Co Investment Adviser first reported a position in Adaptive Biotechnologies in Q4 2024 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Adaptive Biotechnologies position peaked at $1.07M in Q1 2025.
  • 271 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.